Search

Your search keyword '"Mean fluorescence intensity"' showing total 2 results
Start Over Descriptor "Mean fluorescence intensity" Journal indian journal of nephrology
2 results on '"Mean fluorescence intensity"'

1. Correlation of Pretransplant Donor-specific Antibody Assay Using Luminex Crossmatch with Graft Outcome in Renal Transplant Patients.

Author

Vimal, M., Chacko, M. P., Basu, G., and Daniel, D.

Subjects
*CELL surface antigens, *GLOMERULAR filtration rate, *GRAFT rejection, *GRAFT versus host reaction, *HISTOCOMPATIBILITY testing, *HOMOGRAFTS, *IMMUNODIAGNOSIS, *IMMUNOGLOBULINS, *KIDNEY transplantation, *ORGAN donors, *HLA-B27 antigen, *RETROSPECTIVE studies, *PREOPERATIVE period
Abstract

The significance of pretransplant anti-human leukocyte antigen antibody levels that are detectable by more sensitive platforms (including the Luminex platform) yet undetected by complement-dependent cytotoxicity (CDC) assay remains unclear. The aim of this study was to determine the clinical significance of the donor-specific antibody (DSA) assay Luminex crossmatch and its impact on short-term renal graft outcome such as acute rejections, graft survival, and graft function. The results of pretransplant DSA-lymphocyte crossmatching (LCXM) assay in 126 renal allograft recipients whose CDCs crossmatches were negative were retrospectively analyzed for correlation with posttransplant outcomes. Of the 126 recipients, 32 (25.4%) had pretransplant DSA positive. Statistically significant association was found between DSA-LCXM positivity with 14th day estimated glomerular filtration rate (eGFR) (P = 0.05), DSA Class I with 3rd (P = 0.014) and 6th month (P = 0.02) eGFR, DSA Class II with 14th day (P = 0.06) and 1st month (P = 0.10) eGFR, mean fluorescent intensity (MFI) DSA with 7th day (P = 0.08) and 14th day (P = 0.09) eGFR, and maximum MFI DSA with 7th day eGFR (P = 0.09). The posttransplant eGFR was higher at various time intervals in DSA-LCXM-negative patients as compared to DSA-positive patients. However, pretransplant DSA-LCXM results did not predict the rejection episodes, graft loss, and 1-year posttransplant 24 h urine protein. Pretransplant DSA detected by LCXM in patients with a negative CDC does not predict adverse short-term outcomes. However, the difference in posttransplant eGFR supports further investigation in long-term effects. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

2. Correlation of pretransplant donor-specific antibody assay using luminex crossmatch with graft outcome in renal transplant patients

Author

Mary Purna Chacko, M Vimal, Dolly Daniel, and Gopal Basu

Subjects
medicine.medical_specialty, Complement-dependent cytotoxicity, Luminex cross match, 030232 urology & nephrology, Urology, Renal function, Human leukocyte antigen, 030230 surgery, lcsh:RC870-923, Correlation, 03 medical and health sciences, 0302 clinical medicine, medicine, Clinical significance, biology, business.industry, Donor specific antibodies, renal transplantation, lcsh:Diseases of the genitourinary system. Urology, donor-specific antibody, mean fluorescence intensity, body regions, Nephrology, Renal transplant, biology.protein, Original Article, Antibody, business
Abstract

The significance of pretransplant anti-human leukocyte antigen antibody levels that are detectable by more sensitive platforms (including the Luminex platform) yet undetected by complement-dependent cytotoxicity (CDC) assay remains unclear. The aim of this study was to determine the clinical significance of the donor-specific antibody (DSA) assay Luminex crossmatch and its impact on short-term renal graft outcome such as acute rejections, graft survival, and graft function. The results of pretransplant DSA-lymphocyte crossmatching (LCXM) assay in 126 renal allograft recipients whose CDCs crossmatches were negative were retrospectively analyzed for correlation with posttransplant outcomes. Of the 126 recipients, 32 (25.4%) had pretransplant DSA positive. Statistically significant association was found between DSA-LCXM positivity with 14th day estimated glomerular filtration rate (eGFR) (P = 0.05), DSA Class I with 3rd (P = 0.014) and 6th month (P = 0.02) eGFR, DSA Class II with 14th day (P = 0.06) and 1st month (P = 0.10) eGFR, mean fluorescent intensity (MFI) DSA with 7th day (P = 0.08) and 14th day (P = 0.09) eGFR, and maximum MFI DSA with 7th day eGFR (P = 0.09). The posttransplant eGFR was higher at various time intervals in DSA-LCXM-negative patients as compared to DSA-positive patients. However, pretransplant DSA-LCXM results did not predict the rejection episodes, graft loss, and 1-year posttransplant 24 h urine protein. Pretransplant DSA detected by LCXM in patients with a negative CDC does not predict adverse short-term outcomes. However, the difference in posttransplant eGFR supports further investigation in long-term effects.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results